Since first reported having the association with essential hypertension, angiotensin II type 1 receptor (AT1R) A1166C was globally investigated worldwide. However, controversy was found. Furthermore, previous meta-analyses did not adequate to clarify the precise correlation due to some limitations. Therefore, we aimed to perform a meta-analysis concerning the association between AT1R A1166C single-nucleotide polymorphism (SNP) and the risk of essential hypertension with eliminating the limitations of previous studies. A meta-analysis was conducted from February to March 2019. Some information related to sample size of hypertension and control groups and genotype frequencies of hypertension and control groups were extracted from each study. Data were analyzed using fixed or random effect model to determine the overall correlation. A total of 45 papers consisting of 11911 cases and 1340 controls were enrolled for the study. Our overall analysis showed that C allele and AC genotype of AT1R A1166C was associated with 1.18-fold and 1.15-fold respectively increased risk of essential hypertension, while the decreased risk of essential hypertension was observed in A allele and AA genotype. In sub-group analysis, increased risk of essential hypertension was found in C allele, AC genotype, and CC genotype of both Asian population and PCR-RFLP sub-groups, while decreased risk was observed in A allele and AA genotype. Our meta-analysis reveals that AT1R A1166C remains a valuable SNP having an association with the risk of essential hypertension.

中文翻译：

---

血管紧张素II 1型受体A1166C基因多态性与原发性高血压风险的相关性：荟萃分析

自从首次报道与原发性高血压有关以来，血管紧张素 II 1 型受体 (AT1R) A1166C 就在全球范围内展开了调查。然而，发现了争议。此外，由于某些限制，之前的荟萃分析不足以阐明精确的相关性。因此，我们旨在通过消除先前研究的局限性，对 AT1R A1166C 单核苷酸多态性 (SNP) 与原发性高血压风险之间的关联进行荟萃分析。2019年2月至2019年3月进行了荟萃分析，从每项研究中提取了一些与高血压和对照组样本量以及高血压和对照组基因型频率相关的信息。使用固定或随机效应模型分析数据以确定整体相关性。本研究共纳入 45 篇论文，包括 11911 例病例和 1340 例对照。我们的总体分析表明，AT1R A1166C 的 C 等位基因和 AC 基因型分别与原发性高血压风险增加 1.18 倍和 1.15 倍相关，而在 A 等位基因和 AA 基因型中观察到原发性高血压风险降低。在亚组分析中，亚洲人群和PCR-RFLP亚组的C等位基因、AC基因型和CC基因型发现原发性高血压的风险增加，而A等位基因和AA基因型的风险降低。我们的荟萃分析表明，AT1R A1166C 仍然是一个与原发性高血压风险相关的有价值的 SNP。我们的总体分析表明，AT1R A1166C 的 C 等位基因和 AC 基因型分别与原发性高血压风险增加 1.18 倍和 1.15 倍相关，而在 A 等位基因和 AA 基因型中观察到原发性高血压风险降低。在亚组分析中，亚洲人群和PCR-RFLP亚组的C等位基因、AC基因型和CC基因型发现原发性高血压的风险增加，而A等位基因和AA基因型的风险降低。我们的荟萃分析表明，AT1R A1166C 仍然是一个与原发性高血压风险相关的有价值的 SNP。我们的总体分析表明，AT1R A1166C 的 C 等位基因和 AC 基因型分别与原发性高血压风险增加 1.18 倍和 1.15 倍相关，而在 A 等位基因和 AA 基因型中观察到原发性高血压风险降低。在亚组分析中，亚洲人群和PCR-RFLP亚组的C等位基因、AC基因型和CC基因型发现原发性高血压的风险增加，而A等位基因和AA基因型的风险降低。我们的荟萃分析表明，AT1R A1166C 仍然是一个与原发性高血压风险相关的有价值的 SNP。在亚洲人群和 PCR-RFLP 亚组的 C 等位基因、AC 基因型和 CC 基因型中发现原发性高血压的风险增加，而在 A 等位基因和 AA 基因型中观察到风险降低。我们的荟萃分析表明，AT1R A1166C 仍然是一个与原发性高血压风险相关的有价值的 SNP。在亚洲人群和 PCR-RFLP 亚组的 C 等位基因、AC 基因型和 CC 基因型中发现原发性高血压的风险增加，而在 A 等位基因和 AA 基因型中观察到风险降低。我们的荟萃分析表明，AT1R A1166C 仍然是一个与原发性高血压风险相关的有价值的 SNP。